Acute antidepressant response and plasma levels of bupropion and metabolites in a pediatric-aged sample: An exploratory study

Therapeutic Drug Monitoring

Volumn 28, Issue 2, 2006, Pages 190-198

  Burleson Daviss, W ^a   Perel, James M ^b   Brent, David A ^b   Axelson, David A ^b   Rudolph, George R ^b   Gilchrist, Richard ^b   Nuss, Sharon ^b   Birmaher, Boris ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b NONE

Author keywords

Antidepressant response; Bupropion; Metabolites; Plasma concentrations

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DRUG METABOLITE; ERYTHROHYDROBUPROPION; HYDROXYBUPROPION; THREOHYDROBUPROPION; UNCLASSIFIED DRUG;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MONITORING; EXPLORATORY RESEARCH; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; RATING SCALE; SCHOOL CHILD; STEADY STATE; SUICIDE ATTEMPT; SUSTAINED DRUG RELEASE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AREA UNDER CURVE; BUPROPION; CHILD; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 33748106224     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000197093.92559.7a     Document Type: Article

References (24)

1. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:649-657.
2. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996;35:1314-1321.
3. Glod CA, Lynch A, Flynn E, et al. Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs. 2003;16:123-130.
4. Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry. 2001; 40:307-314.
5. Glaxo Smith Kline I. Product Information: Wellbutrin SR (bupropion hydrochloride) sustained-release tablets. Information on File. 2002:1-22.
6. Daviss WB, Perel JM, Rudolph GR, et al. Steady-state pharmacokinetics of bupropion SR in juvenile patients. J Am Acad Child Adolesc Psychiatry. 2005;44:349-357.
7. Glaxo Smith Kline I. Prescribing Information: Wellbutrin XL (bupropion hydrochloride extended-release tablets). 2003:1-27.
8. Goodnick PJ, Dominguez RA, DeVane CL, et al. Bupropion slow-release response in depression: diagnosis and biochemistry. Biol Psychiatry. 1998;44:629-632.
9. Preskorn SH. Antidepressant response and plasma concentrations of bupropion. J Clin Psychiatry. 1983;44:137-139.
10. Golden RN, De Vane CL, Laizure SC, et al. Bupropion in depression. II. The role of metabolites in clinical outcome. Arch Gen Psychiatry. 1988;45:145-149.
11. Goodnick PJ. Blood levels and acute response to bupropion. Am J Psychiatry. 1992;149:399-400.
12. Goodnick PJ, Sandoval R, Brickman A, et al. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. Biol Psychiatry. 1992;32:834-838.
13. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980-988.
14. DeVane CL, Laizure SC, Stewart JT, et al. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol. 1990;10:328-332.
15. Cooper TB, Suckow RF, Glassman A. Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection. J Pharm Sci. 1984;73:1104-1107.
16. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised. In: Publication 76-338. Rockville, MD: US Department of Health, Education and Welfare; 1976.
17. Costello AJ, Benjamin R, Angold A, et al. Mood variability in adolescents: a study of depressed, nondepressed and comorbid patients. J Affect Disord. 1991;23:199-212.
18. Wood A, Kroll L, Moore A, et al. Properties of the mood and feelings questionnaire in adolescent psychiatric outpatients: a research note. J Child Psychol Psychiatry. 1995;36:327-334.
19. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York: Guilford Publications; 1998.
20. Reisby N, Gram LF, Bech P, et al. Imipramine: clinical effects and pharmacokinetic variability. Psychopharmacology (Berl). 1977;54:263-272.
21. Chou TC, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci. 1983;4:450-454.
22. Gessner PK. Isobolographic analysis of interactions: an update on applications and utility. Toxicology. 1995;105:161-179.
23. Settle EC. Bupropion sustained release: side effect profile. J Clin Psychiatry. 1998;4:32-36.
24. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry. 1989;50:256-261.